

Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype

Ione O.C. Woollacott^a Jennifer M. Nicholas^b Carolin Heller^c Martha S. Foiani^c
Katrina M. Moore^a Lucy L. Russell^a Ross W. Paterson^a Ashvini Keshavan^a
Jonathan M. Schott^a Jason D. Warren^a Amanda Heslegrave^c
Henrik Zetterberg^{c-e} Jonathan D. Rohrer^a

^aDementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK; ^bDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK; ^cUK Dementia Research Institute, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK; ^dClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; ^eDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Keywords

Astrocytes · Biomarkers · Cerebrospinal fluid · CHI3L1 · Chitotriosidase · Frontotemporal dementia · Microglia · Neuroinflammation · Progranulin · YKL-40

Abstract

Background: Chronic glial dysfunction may contribute to the pathogenesis of frontotemporal dementia (FTD). Cerebrospinal fluid (CSF) levels of glia-derived proteins YKL-40 and chitotriosidase are increased in Alzheimer's disease (AD) but have not been explored in detail across the spectrum of FTD. **Methods:** We investigated whether CSF YKL-40 and chitotriosidase levels differed between FTD patients and controls, across different clinical and genetic subtypes of FTD, and between individuals with a clinical FTD syndrome due to AD versus non-AD (frontotemporal lobar degeneration, FTLD) pathology (based on CSF neurodegenerative biomarkers). Eighteen healthy controls and 64 people with FTD (behavioural variant FTD, $n = 20$; primary progressive apha-

sia [PPA], $n = 44$: nfvPPA, $n = 16$, svPPA, $n = 11$, lvPPA, $n = 14$, PPA-NOS, $n = 3$) were included. 10/64 had familial FTD, with mutations in *GRN* ($n = 3$), *MAPT* ($n = 4$), or *C9orf72* ($n = 3$). 15/64 had neurodegenerative biomarkers consistent with AD pathology. Levels were measured by immunoassay and compared using multiple linear regressions. We also examined relationships of YKL-40 and chitotriosidase with CSF total tau (T-tau), phosphorylated tau 181 (P-tau) and β -amyloid 1–42 (A β 42), with each other, and with age and disease duration. **Results:** CSF YKL-40 and chitotriosidase levels were higher in FTD, particularly lvPPA (both) and nfvPPA (YKL-40), compared with controls. *GRN* mutation carriers had higher levels of both proteins than controls and *C9orf72* expansion carriers, and YKL-40 was higher in *MAPT* mutation carriers than controls. Individuals with underlying AD pathology had higher YKL-40 and chitotriosidase levels than both controls and those with likely FTLD pathology. CSF YKL-40 and chitotriosidase levels were variably associated with levels of T-tau, P-tau and A β 42, and with each other, depending on clinical syndrome and underlying pathology. CSF YKL-40 but not

chitotriosidase was associated with age, but not disease duration. **Conclusion:** CSF YKL-40 and chitotriosidase levels are increased in individuals with clinical FTD syndromes, particularly due to AD pathology. In a preliminary analysis of genetic groups, levels of both proteins are found to be highly elevated in FTD due to *GRN* mutations, while YKL-40 is increased in individuals with *MAPT* mutations. As glia-derived protein levels generally correlate with T-tau and P-tau levels, they may reflect the glial response to neurodegeneration in FTLD.

© 2020 The Author(s)
Published by S. Karger AG, Basel

Background

Frontotemporal dementia (FTD) causes progressive changes in behaviour (behavioural variant FTD, bvFTD) or language (primary progressive aphasia, PPA), and some individuals have concurrent motor neuron disease (MND) or an atypical parkinsonian disorder such as progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS) [1]. Pathologically, most individuals have frontotemporal lobar degeneration (FTLD) with tau inclusions (FTLD-tau) or transactive response DNA binding protein-43 (TDP-43) inclusions (FTLD-TDP), although some, particularly those with logopenic variant PPA (lvPPA), have underlying Alzheimer's disease (AD) pathology [2, 3]. Around two-thirds of cases are sporadic, but one-third are familial, associated most commonly with mutations in progranulin (*GRN*), microtubule-associated protein tau (*MAPT*) or chromosome 9 open reading frame 72 (*C9orf72*) [1]. Biomarkers are currently lacking that reliably differentiate the pathological changes in vivo in sporadic FTD, can predict onset of disease and guide timely initiation of future treatments in familial FTD, or assess treatment response in future clinical trials.

There is growing evidence that chronic neuroinflammation plays a role in FTD, especially in familial FTD secondary to mutations in *GRN* [4–7], but also in people with *MAPT* [8–10] and *C9orf72* [11–16] mutations, and in sporadic FTD [6, 17–20]. Histological studies of brain tissue from patients with FTD implicate excessive microglial activation [9, 10, 21–29] and astrocytosis [26, 28] but also microglial dystrophy [21] in disease pathogenesis. Although microglia and astrocytes may initially be helpful in neurodegenerative diseases through phagocytosis of aggregated proteins and dying neurons and remodelling of synapses, over time they may become harmful, through chronic activation and release of pro-inflammatory cytokines and other toxic proteins. Accelerated

microglial senescence, dysfunction and reduced phagocytic and supportive capacity may also exacerbate neuronal demise [30]. Inflammatory markers associated with these processes, particularly proteins derived from glial cells, may be detectable and altered in blood or cerebrospinal fluid (CSF), and could be useful biomarkers of chronic neuroinflammation and disease pathogenesis in FTD.

Although it is now well-established that levels of several glia-derived proteins are raised in CSF during various stages of neurodegenerative diseases such as AD or MND, fewer studies have explored how levels are altered in FTD. Three glia-derived proteins have been most extensively explored in neurodegenerative diseases: soluble triggering receptor expressed on myeloid cells 2 (sTREM2), YKL-40 (also known as chitinase-3-like protein 1, CHI3L1) and chitotriosidase (also known as CHIT1). TREM2 is an innate immune receptor expressed by myeloid cells, including microglia and peripheral macrophages [31], and is involved in phagocytosis, survival and migration of microglia. A soluble fragment (sTREM2) is cleaved and detectable in CSF and blood [32]. YKL-40 is a pro-inflammatory molecule released predominantly by activated astrocytes (and to a lesser extent by microglia) into the CSF and by activated peripheral macrophages into blood, which stimulates production of cytokines, and regulates macrophage, microglial and astrocytic function, endothelial cell migration and tumour angiogenesis [33]. Chitotriosidase is a chitin-degrading enzyme expressed by activated microglia (but not by astrocytes) in CSF [34], and by peripheral macrophages in blood [35]. It induces activation of a pro-inflammatory microglial phenotype [34] and has a range of other immunomodulatory functions, including stimulation of chemotactic factors, fibrosis and tissue remodelling [36].

We have recently shown that although CSF sTREM2 levels are not raised in a mixed cohort of individuals with a diagnosis of FTD compared with controls, they are higher in certain subgroups of FTD, such as individuals with a clinical syndrome consistent with FTD but underlying AD pathology, and in symptomatic *GRN* mutation carriers [37]. This has implications for the use of glia-derived proteins as CSF biomarkers in clinical trials for a condition as diverse as FTD. CSF YKL-40 and chitotriosidase levels have not been compared across all the clinical and the main genetic subtypes of FTD or correlated within FTD subgroups with levels of validated CSF neurodegenerative biomarkers used in clinical practice: total tau (T-tau), phosphorylated tau-181 (P-tau) and amyloid beta 1–42 (A β 42).

Table 1. Demographics and CSF biomarker levels of control and FTD groups (overall and clinical subgroups)

	Control	FTD	bvFTD	nfvPPA	svPPA	lvPPA	PPA-NOS
Participants, <i>n</i>	18	64	20	16	11	14	3
Male gender, <i>n</i> (% group)	7 (38.9)	45 (70.3)	19 (95.0)	9 (56.2)	7 (63.6)	7 (50.0)	3 (100.0)
Age at CSF, years, mean (SD)	64.3 (6.6)	64.6 (6.5)	63.4 (7.1)	66.9 (5.9)	60.8 (6.0)	66.5 (6.0)	64.6 (5.4)
Age at onset, years	n/a	59.5 (6.9)	56.1 (6.7)	62.7 (6.1)	56.1 (5.3)	63.0 (6.7)	61.3 (4.1)
Disease duration at CSF, years	n/a	5.1 (3.8)	7.4 (5.6)	4.2 (1.9)	4.7 (2.1)	3.5 (2.0)	3.2 (1.3)
CSF YKL-40, ng/mL	108 (30)	134 (53)	119 (50)	149 (57)	120 (30)	147 (64)	146 (45)
CSF chitotriosidase (raw in pg/mL; <i>natural log values in italics</i>)	1,762 (1,098) 7.3 (0.6)	3,975 (4,356) 7.8 (0.9)	3,730 (3,762) 7.8 (0.9)	4,156 (5,789) 7.8 (0.9)	2,652 (1,609) 7.7 (0.6)	5,330 (5,039) 8.1 (1.1)	3,142 (3,868) 7.5 (1.3)
CSF Aβ42, pg/mL	1,028.5 (208.6)	758.1 (280.7)	828.3 (171.7)	842.5 (298.0)	894.0 (247.4)	444.6 (148.3)	804.3 (434.2)
CSF T-tau, pg/mL	338.8 (82.1)	531.4 (404.5)	351.9 (135.5)	490.6 (247.8)	395.5 (200.3)	968.8 (617.0)	403.3 (208.5)
CSF P-tau, pg/mL	53.1 (10.4)	57.0 (30.6)	45.7 (17.0)	50.6 (18.1)	44.9 (19.8)	91.7 (41.6)	49.0 (14.4)
CSF T-tau/Aβ42 ratio, median (IQR)	0.3 (0.2–0.5)	0.5 (0.3–1.0)	0.4 (0.3–0.5)	0.6 (0.3–0.9)	0.4 (0.3–0.5)	2.0 (1.1–3.2)	0.4 (0.2–1.2)

Values are all mean (standard deviation) except for gender and CSF T-tau/Aβ42 ratio; IQR, interquartile range; n/a, not applicable. Genetic mutations seen in bvFTD were *GRN* ($n = 1$: one S78fs), *MAPT* ($n = 4$: two 10 + 16, two R406W) or *C9orf72* ($n = 3$), and in nfvPPA were *GRN* ($n = 2$: two C31fs).

This study therefore set out to examine how CSF YKL-40 and chitotriosidase levels differ between individuals with a clinical diagnosis of FTD and cognitively normal controls, and between different clinical and genetic subtypes of FTD. We also aimed to clarify how CSF YKL-40 and chitotriosidase levels differ between individuals with similar clinical FTD syndromes but different underlying pathologies: FTLD versus AD, based on the CSF tau/Aβ42 biomarker profile. We also aimed to establish whether YKL-40 or chitotriosidase levels are associated with levels of T-tau, P-tau or Aβ42 in CSF, and to ascertain the relationship between YKL-40 and chitotriosidase levels, across the spectrum of FTD. Finally, we aimed to assess how YKL-40 and chitotriosidase levels are associated with parameters that may affect glial function and are relevant for future clinical trials, such as age, disease duration and sex.

Methods

Participants

The cohort consisted of 64 consecutively recruited individuals with dementia meeting consensus diagnostic criteria for either bvFTD [38] or PPA [39], and 18 healthy cognitively normal con-

trols (as per [37], with the addition of an extra control, recruited subsequent to that study). Cases with additional motor neurone disease were not included in the study. The study was approved by the local NHS Research Ethics Committee and the Health Research Authority. All individuals gave informed written consent.

Within the patient group, 20 had bvFTD, 16 nonfluent variant PPA (nfvPPA), 11 semantic variant PPA (svPPA), 14 logopenic variant PPA (lvPPA) and 3 had a PPA syndrome not otherwise specified (PPA-NOS; not fulfilling criteria of any of the other PPA phenotypes). All participants with FTD were genetically screened for all known FTD causative mutations, including the *C9orf72* expansion. Ten individuals were found to have familial FTD, with mutations in *GRN* ($n = 3$: two C31fs, one S78fs), *MAPT* ($n = 4$: two 10 + 16, two R406W) or *C9orf72* ($n = 3$). All familial cases had a diagnosis of bvFTD except 2 individuals with *GRN* mutations who had nfvPPA. Demographics of the cohort are displayed in Table 1. Disease duration was calculated as the time, in years, between age at clinical onset of symptoms and date of CSF collection.

There was no difference in age at CSF collection between the FTD and control groups ($p = 0.854$), but the svPPA subgroup were younger than the nfvPPA ($p = 0.018$) and lvPPA ($p = 0.031$) subgroups. There was no significant difference in age between any of the genetic subgroups or when compared with controls. There was a higher proportion of males in the FTD group than in the control group ($p = 0.014$), and a higher proportion of males in the bvFTD subgroup versus all other clinical subgroups and controls ($p = 0.006$), other than the PPA-NOS group, where all 3 participants were male (Table 1). There was no significant difference in disease duration between any of the clinical subgroups ($p = 0.105$).

Table 2. Demographics and CSF biomarker levels of control group and dementia groups defined by CSF neurodegenerative biomarker profile

	Control	AD biomarker-negative dementia (CSF T-tau/A β 42 <1.0)	AD biomarker-positive dementia (CSF T-tau/A β 42 >1.0)
Participants, <i>n</i>	18	49	15
Diagnosis	n/a	20 bvFTD, 14 nvPPA, 10 svPPA, 3 lvPPA, 2 PPA-NOS	2 nvPPA, 1 svPPA, 11 lvPPA, 1 PPA-NOS
Male gender, <i>n</i> (% group)	7 (38.9)	36 (73.4)	9 (60.0)
Age at CSF, years	64.3 (6.6)	64.1 (6.7)	65.9 (6.0)
Age at onset, years	n/a	58.6 (6.8)	62.4 (6.7)
Disease duration at CSF, years	n/a	5.6 (4.1)	3.5 (2.1)
CSF YKL-40, ng/mL	108 (30)	125 (45)	163 (67)
CSF chitotriosidase (raw in pg/mL; <i>natural log values in italics</i>)	1,762 (1,098) <i>7.3 (0.6)</i>	3,336 (4,121) <i>7.8 (0.9)</i>	5,975(4,616) <i>8.4 (0.8)</i>
CSF A β 42, pg/mL	1,032.2 (214.3)	833.9 (265.4)	510.5 (165.7)
CSF T-tau, pg/mL	332.6 (82.4)	373.5 (173.0)	1,047.2 (511.3)
CSF P-tau, pg/mL	52.7 (10.6)	44.8 (15.3)	97.0 (34.3)
CSF T-tau/A β 42 ratio, median (IQR)	0.3 (0.2–0.5)	0.4 (0.3–0.7)	1.6 (1.2–3.2)

Values are all mean (standard deviation) except for gender and CSF T-tau/A β 42 ratio; IQR, interquartile range; n/a, not applicable.

CSF Collection, Processing and Biomarker Analysis

For all participants, CSF was collected and stored using standardised procedures [37, 40]. Samples were collected by lumbar puncture in polypropylene tubes, which were immediately transferred to the laboratory. Samples were then centrifuged and the supernatant aliquoted and stored at -80°C within 30 min of arrival. Levels of T-tau, P-tau and A β 42 were measured in CSF using commercially available INNOTEST sandwich enzyme-linked immunosorbent assays (Fujirebio Europe, Gent, Belgium).

CSF YKL-40 levels were measured using the commercially available Human YKL-40 Immunoassay Kit on the Mesoscale Discovery (MSD, Rockville, MD, USA) platform, with all samples assayed in duplicate and measured on the same day by a single operator using the same reagents. Briefly, CSF samples were diluted 1 in 400 with dilution buffer, and the provided standard reconstituted 1 in 20 using dilution buffer and serially diluted 1 in 4 to produce concentrations ranging from 50,000 to 12.2 pg/mL. 150 μL blocking agent was added to each well, and plates sealed and incubated at room temperature shaking at 500 rpm for 1 h. Plates were washed 3 times with 300 μL per well of PBS-T, then 50 μL of either diluted CSF sample, standard or blank (dilution buffer) was added to each well (pre-coated with capture antibody), and plates were sealed and incubated at room temperature shaking at 500 rpm for 2 h. Plates were washed 3 times with 300 μL of PBS-T and 25 μL of detection antibody solution (diluted to 1 in 50) added per well, then sealed and incubated at room temperature shaking at 500 rpm for 2 h. After a further 3 washes with PBS-T, 150 μL of Read

Buffer T (diluted 1 in 2) was added to each well and the plate immediately analysed on the SECTOR Imager using a 4-parameter logistic model with averaged replicates.

CSF chitotriosidase levels were measured using the commercially available CircuLex Human ELISA Kit (MBL International, MA, USA) with all samples assayed in duplicate and measured on the same day by a single operator using the same reagents. Briefly, CSF samples were diluted 1 in 5 with dilution buffer and the provided standard was diluted to produce concentrations ranging from 3,600 to 56.25 pg/mL. 100 μL of either diluted CSF sample, standard or blank (dilution buffer) was added to each well, and plates sealed and incubated at room temperature for 1 h shaking at 300 rpm, then washed 4 times with 350 μL wash buffer. 100 μL of HRP conjugated detection antibody was added and plates sealed and incubated at room temperature for 1 h shaking at 300 rpm, then washed 4 times with 350 μL wash buffer. 100 μL of substrate agent was added to each well and plates were sealed, covered in foil and incubated for 15 min at room temperature shaking at 300 rpm. Finally, 100 μL of stop solution was added to each well in the same order as the substrate agent, and plate absorbance read immediately on a microplate reader at dual wavelengths of 450/540 nm. The concentration of chitotriosidase in each sample was calculated using a four-parameter fitting method based on the standard curve, using values which were blank corrected and averaged over replicates.




Fig. 1. Comparison of CSF YKL-40 levels between groups and subgroups. Graphs show how CSF YKL-40 levels differ across (a) controls and overall FTD group; (b) controls and clinical FTD subgroups; (c) controls and genetic FTD subgroups; (d) controls and CSF biomarker-defined pathological subgroups. Horizontal bars show mean CSF YKL-40 levels and upper and lower 95% confidence intervals for each group; * $p < 0.05$, ** $p < 0.01$.

Participant Stratification

We performed three separate group comparisons:

- 1 By clinical syndrome, comparing bvFTD, nvPPA, svPPA, lvPPA, PPA-NOS, and controls.
- 2 By genetic group, comparing those with *GRN* mutations, *MAPT* mutations, *C9orf72* expansions, and controls.
- 3 By pathological group, comparing those with likely Alzheimer's disease, those with likely FTLT pathology, and controls. We used levels of CSF T-tau and A β 42 to calculate the T-tau/A β 42 ratio for each participant to perform this stratification, classifying all individuals with dementia based on the CSF T-tau/A β 42 ratio, with a cut-off of ≥ 1.0 (AD biomarker-positive, indicating likely AD) and < 1.0 (AD biomarker-negative, indicating likely FTLT) [37, 40] (Table 2). The cognitively normal controls formed a comparison group with all having a CSF T-tau/A β 42 ratio of < 1.0 . No significant difference in age at CSF was seen between these three groups ($p > 0.050$), but disease

duration at CSF was lower in the AD biomarker-positive subgroup than the AD biomarker-negative subgroup ($p = 0.037$). There were significantly more males in the AD biomarker-negative subgroup (73.4%) than in controls (38.9%) and the AD biomarker-positive subgroup (60.0%) ($p = 0.032$).

Statistical Analysis

For YKL-40, levels were detectable in CSF of all individuals, so analyses were performed on all 18 controls and 64 individuals with FTD. For chitotriosidase, 3 individuals (one control, one sporadic bvFTD and one sporadic nvPPA) had persistently undetectable levels of chitotriosidase in CSF, despite assaying their samples again at 1 in 5 dilution and using neat CSF. Approximately 6% of the population possess a homozygous 24-bp duplication in exon 10 of the *CHIT1* gene which leads to a complete enzymatic deficiency of chitotriosidase [41]. These 3 individuals were very likely to be carriers of this mutation, and their levels would bias com-

Table 3. Adjusted mean differences in CSF YKL-40 and Ln(chitotriosidase) levels between all disease groups and subgroups and controls

Groups compared	Mean (SEM) difference in CSF YKL-40 (ng/mL) and Ln (chitotriosidase)	95% confidence intervals for mean difference in CSF YKL-40 (ng/mL) and Ln(chitotriosidase)	<i>p</i> value for comparison for YKL-40 and Ln(chitotriosidase)
FTD vs. control	31.0 (12.9) 0.522 (0.247)	5.23, 56.8 0.031, 1.013	0.019 0.038
<i>Clinical subgroups</i>			
bvFTD vs. control	20.7 (16.9) 0.414 (0.322)	-12.9, 54.4 -0.228, 1.057	0.225 0.202
nfvPPA vs. control	33.8 (16.5) 0.506 (0.317)	5.92, 71.8 -0.126, 1.139	0.021 0.115
svPPA vs. control	20.9 (18.7) 0.362 (0.353)	16.3, 58.1 -0.342, 1.067	0.267 0.309
lvPPA vs. control	36.3 (17.0) 0.788 (0.321)	2.40, 70.2 0.148, 1.428	0.036 0.017
PPA-NOS vs. control	47.4 (30.5) 0.107 (0.571)	-13.2, 108.1 -1.031, 1.245	0.124 0.852
nfvPPA vs. bvFTD	12.5 (19.9) 0.064 (0.386)	-27.3, 52.4 -0.709, 0.837	0.531 0.869
svPPA vs. bvFTD	-4.35 (20.6) -0.066 (0.388)	-45.5, 36.8 -0.845, 0.712	0.833 0.399
lvPPA vs. bvFTD	8.84 (21.1) 0.339 (0.399)	-33.5, 51.2 -0.462, 1.141	0.677 0.399
PPA-NOS vs. bvFTD	21.7 (33.3) -0.355 (0.624)	-44.9, 88.3 -1.61x, 0.897	0.517 0.571
svPPA vs. nfvPPA	-16.9 (21.5) -0.130 (0.411)	-60.0, 26.2 -0.954, 0.693	0.436 0.752
lvPPA vs. nfvPPA	-3.70 (19.0) 0.276 (0.360)	-41.8, 34.4 -0.447, 0.999	0.846 0.448
PPA-NOS vs. nfvPPA	9.14 (33.5) -0.419 (0.631)	-57.9, 76.2 -1.68x, 0.847	0.786 0.509
lvPPA vs. svPPA	13.2 (22.2) 0.406 (0.415)	-31.3, 57.7 -0.426, 1.239	0.555 0.332
PPA-NOS vs. svPPA	26.0 (34.8) -0.289 (0.649)	-43.7, 95.7 -1.591, 1.013	0.458 0.658
PPA-NOS vs. lvPPA	12.8 (33.9) -0.695 (0.634)	-55.2, 80.9 -1.96x, 0.577	0.707 0.278
<i>Genetic subgroups</i>			
GRN vs. control	111.9 (24.4) 1.691 (0.366)	61.5, 162.5 0.930, 2.452	<0.001 <0.001
MAPT vs. control	51.3 (24.2) 0.622 (0.366)	1.10, 101.5 -0.138, 1.382	0.046 0.104
C9orf72 vs. control	-9.17 (26.6) -0.073 (0.399)	-64.3, 45.9 -0.903, 0.758	0.733 0.857
GRN vs. MAPT	60.7 (31.4) 1.06x (0.471)	-4.47, 125.8 0.088, 2.049	0.066 0.034
GRN vs. C9orf72	121.2 (32.6) 1.764 (0.489)	53.5, 188.8 0.747, 2.781	0.001 0.002
MAPT vs. C9orf72	60.5 (29.8) 0.695 (0.448)	-1.36, 122.3 -0.236, 1.626	0.055 0.136
<i>Pathological subgroups</i>			
AD biomarker-positive vs. control	55.5 (16.1) 1.086 (0.296)	23.5, 87.4 0.495, 1.676	0.001 <0.001
AD biomarker-negative vs. control	22.4 (13.1) 0.318 (0.243)	-3.6, 48.4 -0.166, 0.802	0.091 0.194
AD biomarker-positive vs. AD biomarker-negative	30.7 (15.2) 0.783 (0.277)	0.308, 61.0 0.227, 1.338	0.048 0.007

SEM, standard error of the mean. *p* values in bold are significant at *p* < 0.05.

parisons of the groups if included (or assigned the lower limit of detection); hence, they were excluded from the chitotriosidase analysis, leaving 17 controls and 62 individuals with dementia.

All analyses were carried out using STATA14 (Stata Corporation, College Station, TX, USA), with a significance threshold of $p < 0.05$. Shapiro-Wilk tests of raw values and Q-Q plots of residuals from multivariable linear regressions were used to test assumptions of normality.

Assessment of residuals in multivariable linear regression analyses of YKL-40 across groups revealed these were normally distributed and so met the assumptions required for parametric multivariable linear regression analysis. However, the same assessment for chitotriosidase revealed that residuals were not normally distributed, and so chitotriosidase values were natural log (Ln) transformed, which then met assumptions required for multivariable linear regression analysis. Multivariable linear regressions were used to compare YKL-40 and Ln(chitotriosidase) levels between groups (FTD vs. controls and between clinical, pathological and genetic subgroups and vs. controls), adjusting for age and sex in all analyses, and for disease duration in analyses involving comparison of disease groups (but not for genetic subgroups due to small sample size). Post hoc pairwise tests were used to compare individual subgroups.

In each group (except genetic subgroups due to small sample size), multivariable linear regressions were used to investigate the association between:

- YKL-40 or Ln(chitotriosidase) levels and levels of CSF T-tau, P-tau and A β 42, adjusted for age and sex (for the control group) and for age, sex and disease duration (for disease groups). Due to a non-linear relationship between T-tau levels and YKL-40 and chitotriosidase levels, T-tau values were Ln transformed and all regression analyses performed using Ln(T-tau).
- Ln(chitotriosidase) and Ln transformed YKL-40 levels (due to a non-linear relationship between raw values), adjusted for age and sex, and for disease groups, disease duration as well.
- YKL-40 or Ln(chitotriosidase) and both age at CSF collection (adjusted for sex in the control group and both sex and disease duration in disease groups) and disease duration at CSF collection (for disease groups, adjusted for age and sex).

Mann-Whitney U tests were used to compare protein levels between males and females in each group (but not within genetic subgroups due to small sample size).

Results

CSF YKL-40 and Chitotriosidase Levels Are Higher in Certain FTD Syndromes than Controls

CSF YKL-40 levels were higher overall in individuals with a clinical FTD syndrome than in controls (mean [SD] = 134 [53] vs. 108 [30] ng/mL, $p = 0.019$; Fig. 1a, Tables 1, 3). However, this varied by clinical subtype (Fig. 1b; Tables 1, 3): YKL-40 levels were highest in individuals with nvPPA (149 [57] ng/mL, $p = 0.021$ vs. controls) and lvPPA (147 [64] ng/mL, $p = 0.036$). Although individuals with PPA-NOS had similarly high YKL-40 levels (146 [45] ng/mL), the small size of this group meant

that the difference from controls was not statistically significant ($p = 0.124$). No significant differences were seen between YKL-40 levels in bvFTD or svPPA subgroups compared with controls, and there were no significant differences between clinical subgroups (Fig. 1b).

CSF chitotriosidase levels were also significantly higher overall in individuals with a clinical FTD syndrome compared with controls (Fig. 2a, Tables 1, 3; FTD: mean [SD] = 3,795 [4,358] vs. controls: 1,762 (1,098) pg/mL, $p = 0.038$). Although a trend towards higher levels was seen in all clinical subgroups (Fig. 2b; Tables 1, 3), this only reached statistical significance in lvPPA (5,240 [5,039] pg/mL, $p = 0.017$) and there were no significant differences between clinical subgroups.

CSF YKL-40 and Chitotriosidase Levels Differ by Underlying Gene Mutation in FTD

GRN mutation carriers had significantly higher levels of YKL-40 compared with controls (mean [SD] = 226 [42] vs. 108 [30] ng/mL, $p < 0.001$; Fig. 1c) and compared with C9orf72 expansion carriers (99 [40] ng/mL, $p = 0.001$), with a trend to a higher level compared with MAPT mutation carriers (150 [69] ng/mL, $p = 0.066$). MAPT mutation carriers also had significantly higher YKL-40 levels than controls ($p = 0.046$; Fig. 1c), with a trend to higher levels compared with C9orf72 expansion carriers ($p = 0.055$).

GRN mutation carriers had much higher levels of chitotriosidase compared with controls (mean [SD] = 9,492 [5,143] vs. 1,762 [1,098] pg/mL, $p < 0.001$), MAPT mutation carriers (2,770 [1,664] pg/mL, $p = 0.034$) and C9orf72 expansion carriers (1,688 [1,345] pg/mL, $p = 0.002$; Fig. 2c). However, in contrast to YKL-40, MAPT mutation carriers had more similar chitotriosidase levels to controls ($p = 0.104$) and C9orf72 expansion carriers ($p = 0.136$).

CSF YKL-40 and Chitotriosidase Levels Are Higher in FTD Syndromes due to Underlying AD Pathology

Levels of both YKL-40 and chitotriosidase were highest in the AD biomarker-positive subgroup (YKL-40 mean [SD] = 163 [67] ng/mL; chitotriosidase = 5,975 [4,616] pg/mL) with significantly higher levels of both proteins in this subgroup compared with the AD biomarker-negative subgroup (YKL-40: 125 [45] ng/mL; $p = 0.048$, Fig. 1d; chitotriosidase: 3,336 [4,121] pg/mL, $p = 0.007$, Fig. 2d; Tables 2, 3) and also compared with controls (YKL-40: 108 [30] ng/mL, $p = 0.001$, Fig. 1d; chitotriosidase: 1,762 [1,098] pg/mL, $p < 0.001$, Fig. 2d; Tables 2, 3). There was a non-significant trend to a higher level




Fig. 2. Comparison of CSF chitotriosidase levels between groups and subgroups. Graphs show how CSF Ln(chitotriosidase) levels differ across (a) controls and overall FTD group; (b) controls and clinical FTD subgroups; (c) controls and genetic subgroups; (d) controls and CSF biomarker-defined pathological subgroups. Horizontal bars show mean CSF Ln(chitotriosidase) levels and upper and lower 95% confidence intervals for each group; * $p < 0.05$, ** $p < 0.01$.

of each protein in the AD biomarker-negative subgroup versus controls (YKL-40: $p = 0.091$, Fig. 1d; chitotriosidase: $p = 0.194$, Fig. 2d; Tables 2, 3).

CSF YKL-40 and Chitotriosidase Are Variably Associated with T-tau, P-tau and A β 42

Associations between levels of CSF neurodegenerative biomarkers T-tau, P-tau and A β 42 and levels of CSF YKL-40 (Fig. 3) or chitotriosidase (Fig. 4) varied according to clinical diagnosis and CSF biomarker profile (i.e., underlying pathology). In controls, CSF YKL-40 and chitotriosidase were not significantly associated with any biomarker. In the overall FTD (dementia) group, CSF

YKL-40 and chitotriosidase levels were significantly positively associated with both T-tau and P-tau levels, and there was a small, negative association of chitotriosidase with A β 42 levels. For YKL-40: T-tau β (95% CI) = 42.996 (24.878, 61.113), $p < 0.001$ (Fig. 3a); P-tau β = 0.722 (0.339, 1.105), $p < 0.001$ (Fig. 3b); A β 42 β = -0.003 (-0.051, 0.045), $p = 0.907$ (Fig. 3c). For chitotriosidase: T-tau β = 0.668 (0.306, 1.030), $p < 0.001$ (Fig. 4a); P-tau β = 0.009 (0.001, 0.016), $p = 0.028$ (Fig. 4b); A β 42 β = -0.0009 (-0.0017, -0.0002), $p = 0.044$ (Fig. 4c).

Most clinical subgroups showed positive slopes for the association between YKL-40 and T-tau or P-tau levels (Fig. 3d, e), but this only reached significance in certain




Fig. 3. Relationship between CSF YKL-40 and CSF neurodegenerative biomarker levels. Graphs show associations between CSF YKL-40 and T-tau (**a**), P-tau (**b**) and A β 42 (**c**) levels for controls and overall FTD group, between YKL-40 levels and T-tau (**d**), P-tau (**e**) and A β 42 (**f**) levels for controls and clinical FTD subgroups, and between YKL-40 levels and T-tau (**g**), P-tau (**h**) and A β 42 (**i**)

levels for controls and CSF biomarker-defined pathological subgroups. T-tau values were Ln transformed before analysis. Lines are group regression lines adjusted for age and sex (controls) and age, sex and disease duration (overall dementia group, clinical subgroups and biomarker-defined pathological subgroups). See main text for individual β and p values for each association.

subgroups. YKL-40 levels were significantly positively associated with T-tau levels in bvFTD (β [95% CI] = 109.3 [80.6, 138.1], $p < 0.001$) and nfvPPA ($\beta = 69.9$ [21.2, 118.6], $p = 0.009$), and with P-tau levels in bvFTD ($\beta = 1.746$ [0.607, 2.885], $p = 0.005$) and lvPPA ($\beta = 1.020$

[0.199, 1.841], $p = 0.020$). YKL-40 levels were not associated with A β 42 levels in most subgroups, except in lvPPA (Fig. 3f), where there was a significant positive association ($\beta = 0.274$ [0.043, 0.506], $p = 0.025$). Chitotriosidase levels were positively associated with T-tau or P-tau levels only




Fig. 4. Relationship between CSF chitotriosidase and CSF neurodegenerative biomarker levels. Graphs show associations between CSF chitotriosidase and T-tau (**a**), P-tau (**b**) and Aβ42 (**c**) levels for controls and overall FTD group, between chitotriosidase levels and T-tau (**d**), P-tau (**e**) and Aβ42 (**f**) levels for controls and clinical FTD subgroups, and between chitotriosidase levels and T-tau (**g**), P-tau (**h**) and Aβ42 (**i**) levels for controls and CSF biomarker-

defined pathological subgroups. Chitotriosidase and T-tau values were Ln transformed before analysis. Lines are group regression lines adjusted for age and sex (controls) and age, sex and disease duration (overall dementia group, clinical subgroups and biomarker-defined pathological subgroups). See main text for individual β and p values for each association.

in certain clinical subgroups (Fig. 4d, e). There was a significant association between chitotriosidase and T-tau levels in bvFTD ($\beta = 1.312$ [0.132, 2.491], $p = 0.003$) and lvPPA ($\beta = 0.937$ [0.231, 1.642], $p = 0.015$) and with P-tau levels in lvPPA ($\beta = 0.014$ [0.001, 0.027], $p = 0.043$). Al-

though most clinical subgroups except lvPPA had borderline negative associations between chitotriosidase and Aβ42 levels, these did not reach significance (Fig. 4f).

Although both pathological subgroups (AD biomarker-positive and AD biomarker-negative) and controls




Fig. 5. Relationship between chitotriosidase and YKL-40 levels in CSF. Graphs show CSF chitotriosidase levels vs. CSF YKL-40 levels for controls and overall FTD group (**a**), clinical FTD subgroups (**b**) and controls and CSF biomarker-defined pathological subgroups (**c**). Chitotriosidase and YKL-40 values were Ln transformed before analysis. Lines in **a** are group regression lines adjusted for age and sex (controls) and age, sex and disease duration (dementia

group). Lines in **b** are group regression lines for clinical subgroups adjusted for age, sex and disease duration. Lines in **c** are group regression lines adjusted for age and sex (controls) and age, sex and disease duration (CSF biomarker-defined pathological subgroups). See main text for individual β and p values for each association.

seemed to have positive associations between YKL-40 and T-tau and P-tau levels (Fig. 3g, h), associations were only significant in the AD biomarker-negative subgroup: T-tau β (95% CI) = 62.064 (37.676, 86.451), $p < 0.001$; P-tau β = 1.055 (0.261, 1.849), $p = 0.010$. The AD biomark-

er-positive subgroup had a significant, positive association between YKL-40 and A β 42 levels ($\beta = 0.226$ [0.011, 0.442], $p = 0.041$, Fig. 3i). There were no significant associations between chitotriosidase levels and T-tau, P-tau or A β 42 levels in any pathological subgroup or controls




Fig. 6. Relationship between CSF YKL-40 or chitotriosidase levels and age at CSF. Graphs show CSF YKL-40 levels vs. age in controls and overall FTD group (a) and clinical FTD subgroups (b), and CSF chitotriosidase levels vs. age in controls and overall FTD group (c) and clinical FTD subgroups (d). Chitotriosidase values were Ln transformed before analysis. Lines in a and c are group

regression lines adjusted for sex (controls) and sex and disease duration (dementia group). Lines in b and d are group regression lines for individual clinical subgroups adjusted for sex and disease duration. See main text for individual β and p values for each association.

(Fig. 4g-i), although there was a trend towards a positive association between chitotriosidase and T-tau in the AD biomarker-negative subgroup ($\beta = 0.631 [-0.003, 1.265]$; $p = 0.051$, Fig. 4g).

CSF Chitotriosidase Is Positively Associated with YKL-40 in FTD

CSF chitotriosidase levels were positively associated with YKL-40 levels within the whole cohort (β [95% CI] = 1.008 [0.507, 1.509], $p < 0.001$) and in the overall FTD (dementia) group ($\beta = 1.094 [0.508, 1.680]$, $p <$

0.001, Fig. 5a) but not in controls ($\beta = -0.203 [-1.605, 1.199]$, $p = 0.774$, Fig. 5a). Levels of both proteins were also positively associated in most clinical subgroups (Fig. 5b) but reached significance only in bvFTD ($\beta = 1.369 [0.399, 2.340]$, $p = 0.007$) and nfvPPA ($\beta = 1.388 [0.034, 2.742]$, $p = 0.045$). Levels were positively associated in the AD biomarker-negative subgroup ($\beta = 1.226 [0.556, 1.896]$, $p = 0.001$; Fig. 5c), but this did not reach significance in the AD biomarker-positive subgroup ($\beta = 0.275 [-0.781, 1.332]$, $p = 0.604$; Fig. 5c).




Fig. 7. Relationship between CSF YKL-40 or chitotriosidase levels and disease duration at CSF. Graphs show CSF YKL-40 levels vs. disease duration in the overall FTD group (**a**) and clinical FTD subgroups (**b**), and CSF chitotriosidase levels vs. disease duration

in the overall FTD group (**c**) and clinical FTD subgroups (**d**). Chitotriosidase values were Ln transformed before analysis. Lines in **a–d** are group regression lines adjusted for age and sex. See main text for individual β and p values for each association.

CSF YKL-40 but Not Chitotriosidase Levels Are Associated with Age

CSF YKL-40 levels were positively associated with age at CSF in the whole cohort (β [95% CI] = 1.989 [0.352, 3.625], $p = 0.018$). A similar magnitude of association was seen in the FTD group ($\beta = 1.864$ [0.059, 3.670], $p = 0.043$, Fig. 6a) and the control group ($\beta = 2.467$ [−1.074, 6.007], $p = 0.169$; Fig. 6a). Although most of the clinical subgroups (apart from nvfPPA and PPA-NOS; Fig. 6b) and both pathological subgroups appeared to have a positive slope for the association between YKL-40 levels and age, none reached significance. Chitotriosidase levels

were not significantly associated with age in either the whole cohort ($\beta = 0.007$ [−0.024, 0.378], $p = 0.661$) or the FTD ($\beta = 0.004$ [−0.064, 0.073], $p = 0.904$; Fig. 6c) or control ($\beta = 0.008$ [−0.026, 0.042], $p = 0.628$; Fig. 6c) groups, or in any of the clinical (Fig. 6d) or pathological subgroups.

There were no significant associations between either YKL-40 (Fig. 7a) or chitotriosidase (Fig. 7c) levels and disease duration in the FTD group (YKL-40: $\beta = -1.874$ [−5.403, 1.655], $p = 0.292$; chitotriosidase: $\beta = -0.016$ [−0.082, 0.051], $p = 0.631$) or within any of the clinical (Fig. 7b, d) or pathological subgroups.

CSF YKL-40 and chitotriosidase levels did not differ significantly between males and females in the whole cohort or in FTD or control groups, or in any of the clinical or pathological subgroups.

Discussion

This study shows that levels of two glia-derived proteins, YKL-40 and chitotriosidase, are raised in the CSF of individuals with a clinical diagnosis of FTD compared with controls. However, levels are not consistently raised across all clinical subtypes, with highest YKL-40 levels in lvPPA and nfvPPA, and highest chitotriosidase levels in lvPPA. Individuals with a clinical syndrome consistent with FTD but a CSF neurodegenerative biomarker profile consistent with AD pathologically have particularly high levels of both proteins compared with controls, and higher levels than individuals with a diagnosis of FTD and non-AD like CSF biomarkers (likely FTLD), who have a non-significant trend to higher levels than controls. In a smaller subgroup analysis, both YKL-40 and chitotriosidase levels are highly elevated in FTD due to *GRN* mutations, and YKL-40 levels are also elevated in FTD due to *MAPT* mutations. Associations between YKL-40 and chitotriosidase levels, and with T-tau, P-tau and A β 42 levels, vary depending on clinical diagnosis and CSF biomarker profile. CSF YKL-40 levels, but not chitotriosidase levels, are associated with age, and neither are associated with disease duration.

Raised CSF YKL-40 levels have previously been demonstrated in several FTD cohorts versus controls [33, 42–49], including in familial FTD [48], and compared with individuals with primary psychiatric diagnoses [50]. In contrast, few studies have examined CSF chitotriosidase levels in FTD. One study found higher chitotriosidase levels in FTD (in cases without CSF biomarker or pathological confirmation) compared with healthy controls [51], but another found similar levels to controls in a mixed familial FTD cohort [48]. Our results and results from previous biomarker and histological studies suggest significant glial activation is present in individuals with clinical diagnoses of FTD. However, previous biomarker studies have included individuals with different clinical syndromes, gene mutations and underlying pathologies (or co-pathologies) within FTD cohorts. This has limited our understanding of how glia-derived proteins vary in CSF across the spectrum of FTD, and how these biomarkers may be useful for clinical trials targeting different FTD subgroups. Our study therefore aimed to elucidate how

levels of YKL-40 and chitotriosidase vary across the spectrum of FTD by examining these proteins at the subgroup level.

CSF YKL-40 and chitotriosidase levels were significantly raised in several, but not all, clinical subtypes of FTD and there was significant variability in levels within clinical subgroups. The highest YKL-40 levels were seen in lvPPA and nfvPPA, but the PPA-NOS subgroup also had high levels (likely not reaching significance when compared with controls due to small sample size). The highest chitotriosidase levels were in lvPPA, but other clinical subgroups showed non-significant trends towards higher levels than controls. There were no significant differences in levels between clinical subgroups. Very few studies have explored this previously: one study examining CSF YKL-40 levels in bvFTD, nfvPPA, svPPA, CBS and PSP compared with controls found raised levels in all syndromes (except PSP) and no significant differences between FTD subgroups, although individuals with lvPPA were not delineated from an accompanying typical AD group [43]. A study of CSF chitotriosidase levels in FTD found no significant difference between bvFTD and PPA, or between PPA subtypes, although PPA subgroups were much smaller than in our cohort and lacked biomarker or pathological correlation [51]. Different clinical subtypes of FTD may have widely differing pathologies, co-pathologies and disease mechanisms and hence differing degrees of glial activation which could affect YKL-40 and chitotriosidase release. In particular, patients with MND have much higher CSF YKL-40 levels [46, 48, 52–55] and CSF chitotriosidase levels or activity [34, 48, 51, 54–57] than controls, and higher chitotriosidase levels than in FTD [51], so our study did not include individuals with FTD-MND to avoid confounding results. The majority (78%) of our lvPPA subgroup had a CSF biomarker profile consistent with AD (rather than FTLD), and our nfvPPA subgroup contained 2 individuals with AD-like CSF biomarkers and 2 individuals with *GRN* mutations. In contrast, most individuals with bvFTD or svPPA had non-AD-like biomarkers and either a smaller percentage of (bvFTD) or no *GRN* mutations. We therefore hypothesise that the particularly high YKL-40 and chitotriosidase levels in lvPPA and high YKL-40 levels in nfvPPA may be due to more pronounced glial activation in individuals with underlying AD pathology and *GRN* mutations.

We were able to explore this further by stratifying our FTD cohort by CSF neurodegenerative biomarker profile (T-tau/A β 42 ratio) rather than by clinical diagnosis. This was helpful in a previous study to demonstrate that

CSF sTREM2 levels are raised in individuals with a clinical diagnosis of an FTD syndrome but AD-like CSF biomarkers, particularly IvPPA, compared with controls, but not in those with likely FTLT [37]. By repeating this approach, we confirm that there are also much higher levels of YKL-40 and chitotriosidase in the CSF of individuals with an FTD syndrome but AD-like CSF biomarkers compared with controls, and higher levels than in individuals with non-AD-like CSF (i.e., likely FTLT). Patients with typical amnesic AD have elevated levels of glia-derived proteins in CSF compared with controls, including YKL-40 [42, 47, 58–65, 66–69], sTREM2 [70–73], chitotriosidase [51, 59, 74, 75], glial fibrillary acidic protein [76–78] and S100beta [79–81]. This suggests there is pronounced astrocytic and microglial activation in association with AD pathology. The soluble phosphorylated tau species found in patients with amnesic AD are highly toxic to microglia, resulting in pronounced microglial dysfunction and dystrophy [82] and tau oligomers co-localise with microglia, astrocytes and pro-inflammatory cytokines in patients with AD and FTLT [26]. Patients with clinical FTD but underlying AD pathology would therefore also be expected to have very high levels of glia-derived proteins compared with controls, and data from this study and our previous study [37] support this.

Although CSF YKL-40 and chitotriosidase levels did not differ significantly between individuals with FTD and non-AD-like CSF biomarkers (likely FTLT) and controls, there was a trend towards higher levels of both proteins in this group. There was also significant intra-group variability in protein levels, particularly for chitotriosidase, suggesting glial activation may vary considerably according to the FTLT subtype or disease mechanism. Other studies have explored this by stratifying pathologically confirmed FTLT groups and found higher CSF YKL-40 levels in both FTLT-tau and FTLT-TDP than in individuals with subjective memory impairment, and in FTLT-tau compared with AD [43, 44, 49]. One study found higher YKL-40 levels in “pure” FTLT-tau (excluding AD pathology) than in patients with FTLT-TDP or AD [44], although others have found higher levels in FTLT-TDP (but not FTLT-tau) compared with controls [43, 45]. Differences in the number of genetic FTD cases in FTLT subgroups or inclusion of individuals with co-pathology are likely to have contributed to these disparities between studies. FTLT-TDP cohorts have included patients with concurrent MND [45], or patients with *GRN* mutations [43] who we demonstrate have very high levels of both YKL-40 and chitotriosidase. FTLT-tau co-

horts have included differing numbers of *MAPT* cases, who we show have particularly raised YKL-40 levels. This variability in levels according to pathology or disease mechanism has implications for the use of inflammatory proteins as fluid biomarkers in both research studies and clinical trials for a disease as pathologically diverse as FTD. It also emphasises the importance of detailed stratification of cohorts or use of CSF biomarker or pathological correlation in biomarker studies of FTD.

Although we were unable to divide our cohort into FTLT subtypes due to a lack of cases with pathological confirmation, we were able to include a small number of individuals with familial FTD, enabling an exploratory analysis of CSF YKL-40 and chitotriosidase levels in a small number of individuals with known pathology (FTLT-TDP: *GRN* or *C9orf72* mutations or FTLT-tau: *MAPT* mutations), and also differing disease mechanisms despite similar pathology (*GRN* and *C9orf72* mutations). *GRN* mutation carriers had very elevated YKL-40 and chitotriosidase levels, and *MAPT* mutation carriers had high YKL-40 levels compared with controls. Very few studies have examined glia-derived CSF biomarkers in individuals with genetic FTD. In a recent study, CSF YKL-40 levels, but not CSF chitotriosidase levels, were significantly elevated in 23 familial FTD cases (combining *C9orf72*, *GRN* or *MAPT* mutation carriers) compared with controls [48]. However, genetic subgroup analyses were not performed to analyse differences between mutation types and the genetic group contained a significant proportion of patients with *C9orf72* expansions (15/23) (who we found to have similar levels of both proteins to controls), which may have influenced results. The highly elevated levels of YKL-40 and chitotriosidase in our *GRN* mutation group is consistent with multiple studies showing elevated levels of other inflammatory markers in *GRN* mutation carriers [6, 19, 37, 83–85]. *GRN* haploinsufficiency results in significant microglial dysfunction and activation [4, 21, 86], which could lead to excessive YKL-40 and chitotriosidase release as a mutation-specific effect, exacerbated by the general glial response to neurodegeneration, perhaps explaining the higher levels in *GRN* than *C9orf72* mutation carriers. Patients with heterozygous *GRN* mutations also display significant lysosomal dysfunction [87, 88], which could exacerbate chitotriosidase release into CSF. Plasma [35] and CSF [89, 90] chitotriosidase are highly elevated in the lysosomal storage disorder Gaucher’s disease, where macrophages are chronically activated [35, 91] and plasma levels are already used for monitoring treatment response [92]. Serum YKL-40 levels are also raised (and serum *GRN* levels

are reduced) in Gaucher's disease, and recombinant GRN reduces serum YKL-40 levels in *GRN* knockout mice and in fibroblasts from patients with Gaucher's disease [91]. This strengthens the evidence for a link between GRN haploinsufficiency, glial activation, and lysosomal dysfunction, which could be detectable at an early stage, and reversible, in *GRN* mutation carriers.

The high YKL-40 levels observed in *MAPT* carriers are consistent with elevated CSF YKL-40 levels in FTLD-tau [43, 49] and colocalisation of activated astrocytes with tau oligomers in P301S *MAPT* mouse models [26]. There are also many activated microglia surrounding phosphorylated-tau positive neurons in *MAPT* P301S mice [8] or patients with P301S mutations [9] and pronounced frontotemporal microglial activation in *MAPT* mutation carriers [10]. This suggests that certain FTLD-tau pathologies, as well as tau in AD, may promote YKL-40 release. CSF chitotriosidase levels were also slightly raised in *MAPT* carriers, but this did not reach significance compared with controls. This may have been due to the small group size, or perhaps there is greater astrocytosis than microglial activation associated with certain *MAPT* mutations.

In order to explore further how biomarkers of glial activation link to neurodegeneration, we examined relationships between YKL-40 and chitotriosidase levels and CSF neurodegenerative biomarkers that are used in clinical practice and which reflect neuronal injury and tau pathology (T-tau and P-tau) and amyloid pathology (A β 42). Overall, both YKL-40 and chitotriosidase levels were positively associated with T-tau and P-tau levels in FTD, but this association only reached significance in certain clinical subgroups. For T-tau, there was a significant association with YKL-40 in bvFTD and nfvPPA and with chitotriosidase in bvFTD and lvPPA. For P-tau, there was a significant association with YKL-40 in bvFTD and lvPPA and with chitotriosidase in lvPPA. There was a small positive association between A β 42 levels and YKL-40 in lvPPA, and although most subgroups seemed to have a negative association between A β 42 and chitotriosidase, none reached significance. This variation in the strength of association between biomarkers may be explained by underlying pathologies (different FTLD subtypes or AD) being associated with varying degrees of glial activation, neurodegeneration and tau pathology, or differences in clinical subgroup sizes. Positive associations between levels of CSF YKL-40 or chitotriosidase and neurodegenerative biomarkers have been identified in many studies of typical AD, particularly for T-tau [42, 47, 58, 65–68, 93] and P-tau [42, 58, 65, 66, 68, 69, 93, 94].

Consistent with this, there was a strong association between levels of P-tau and both glia-derived proteins in our lvPPA subgroup, where most individuals had AD-like biomarkers and high levels of both YKL-40 and chitotriosidase, suggestive of significant hyperphosphorylated tau pathology and glial activation. Our results are consistent with strong associations between T-tau and YKL-40 identified in other studies of FTD [49, 58], but to our knowledge no studies have explored associations between chitotriosidase and neurodegenerative biomarkers in FTD. Our findings suggest that chitotriosidase release may be similarly linked to neurodegeneration in FTD.

In individuals with FTD but AD-like CSF (AD biomarker-positive subgroup), there were positive slopes for the association between YKL-40 and both T-tau and P-tau levels, but neither association reached significance, and chitotriosidase levels were not significantly associated with any neurodegenerative biomarker. This contrasts with the strong associations between sTREM2 and both T-tau and P-tau levels in this group found previously [37], and in studies of amnesic AD. However, levels of YKL-40 and chitotriosidase were very high in most individuals within this subgroup, so a lack of variability combined with a relatively small sample size may have hampered our ability to detect weak associations between biomarkers. It is unclear why there was a positive association between A β 42 and YKL-40 in this subgroup, although others have shown a similar association [47, 66] or negative [94] or no significant [42] association with A β 42 in AD. In individuals with likely FTLD (AD biomarker-negative subgroup), there was a significant positive association between YKL-40 and both T-tau and P-tau levels and a trend towards a positive association between chitotriosidase and T-tau levels. This suggests that glial activation may correlate with the degree of neuronal injury, and perhaps also tau pathology, in individuals with FTLD, supporting histopathological studies showing pronounced astrocytosis and microgliosis in FTLD, particularly tauopathies [9, 10, 26, 28, 95].

We also analysed associations between YKL-40 and chitotriosidase levels in our cohort, which to our knowledge has not been explored directly in FTD previously, although these seem to correlate moderately in AD [74] and in a combined familial MND and FTD cohort [48]. There was a strong positive association between levels of both proteins in FTD overall, and in most clinical subgroups, although this reached significance only in bvFTD and nfvPPA. Levels of YKL-40 and chitotriosidase were also highly associated in the AD biomarker-negative sub-

group, but this did not reach significance in the AD biomarker-positive subgroup, again likely due to high levels of both proteins in most individuals and smaller sample size. These results suggest that astrocytic and microglial activation arise in tandem in FTD syndromes due to FTLD and perhaps AD pathology.

Finally, we examined relationships between CSF YKL-40 and chitotriosidase levels and relevant clinical parameters such as age, disease duration and sex, which could independently affect glial activation. Age was strongly associated with YKL-40 levels in the whole cohort and in the FTD group, consistent with previous studies of YKL-40 in AD [47, 61, 68] and FTD [43, 45, 49], and a strong association between sTREM2 and age in FTD [37]. This may reflect increased glial activation associated with aging, especially within the context of neurodegeneration, and emphasises the importance of future studies of glia-derived biomarkers in neurodegenerative disease cohorts exploring associations with age and, where applicable, adjusting group comparisons for age. There was no significant association between age and chitotriosidase levels in any group. In MND, plasma chitotriosidase activity was not associated with age [57], and most studies of CSF chitotriosidase in AD and FTD have found no association with age [48, 59, 74]. It is unclear why this differs from YKL-40, but perhaps age has less of an influence on microglial chitotriosidase release. We found no association between either YKL-40 or chitotriosidase and disease duration in FTD, in contrast to sTREM2, where we previously described a negative association between CSF sTREM2 levels and disease duration [37], but consistent with a study of YKL-40 in FTD, where there was no association with disease duration [43]. However, our current data are cross-sectional, so we were unable to explore longitudinal changes in YKL-40 or chitotriosidase levels to confirm whether these markers alter throughout the disease course. Lastly, we found no difference in YKL-40 or chitotriosidase levels between males and females in any group, suggesting limited influence of sex on release of these proteins into CSF in both healthy individuals and patients with FTD.

Limitations of this study include the small size of some of the subgroups, which may have limited our power to detect significant differences between groups. However, this is inherent to a rare disease such as FTD which has multiple phenotypes, and difficult to avoid when analysing biomarker levels across a broad spectrum of disease, while confining CSF collection and biomarker analysis to one site in order to minimise inter-centre variation. Our patient cohort contained both individuals with a clinical

diagnosis of an FTD syndrome most likely due to FTLD (bvFTD, svPPA and nvPPA) and those more commonly associated with AD pathology (lvPPA). The use of clinical diagnosis rather than pathological confirmation as an inclusion criterion meant a combination of different pathologies and mutations in the FTD group may have affected YKL-40 and chitotriosidase levels in this group overall. However, we were able to dissect out differences in protein levels between broad pathological entities (FTLD vs. AD) and gene mutations through stratification of the FTD group by CSF biomarker profile and through a preliminary analysis by mutation type. We also intentionally used a stringent cut-off of T-tau/A β 42 ratio >1.0 to minimise misclassification of individuals into the wrong pathological subgroup, as employed previously [37]. In addition, all individuals with FTD were phenotyped in detail, meeting recent diagnostic criteria for bvFTD [38] or PPA [39].

Conclusions

We show that levels of two glia-derived proteins, YKL-40 and chitotriosidase, are higher in the CSF of individuals with a clinical diagnosis of FTD than in cognitively normal controls. However, levels are higher in individuals with an FTD syndrome due to underlying AD pathology (particularly lvPPA) than due to FTLD. We display preliminary evidence that there are mutation-specific differences in YKL-40 and chitotriosidase levels, with particularly pronounced elevations of YKL-40 and chitotriosidase in *GRN* mutation carriers, and YKL-40 in *MAPT* mutation carriers, which may remain undetected in mixed genetic FTD cohorts. As CSF YKL-40, and perhaps chitotriosidase, levels correlate with neurodegenerative biomarkers, particularly T-tau, and with each other, in individuals with likely FTLD, these proteins may reflect extensive astrocytic and microglial activation arising in tandem with neurodegeneration in individuals with FTLD.

Future studies should analyse CSF YKL-40 and chitotriosidase levels within larger cohorts of individuals with FTD, across a variety of clinical subgroups, and ideally in pathologically confirmed cases across the full spectrum of FTLD subtypes, with separate sporadic and genetic subgroups. Inclusion of a larger number of cases with mutations in *GRN*, *MAPT* and *C9orf72* would enable confirmation of our preliminary observations of higher protein levels in symptomatic *GRN* and *MAPT* mutation carriers. Assessment of levels in presymptomatic mutation carri-

ers could establish when these change prior to expected symptom onset. Exploration of relationships between baseline and longitudinal measurements of CSF YKL-40 and chitotriosidase levels, and other markers of the disease process (such as serum or CSF neurofilament light levels or frontal lobe atrophy rate) in individuals with FTD, and presymptomatic individuals, would be extremely valuable. This could improve understanding of how chronic neuroinflammation links to neurodegeneration, enable determination of whether these proteins can be used as biomarkers of disease stage, intensity and progression, and provide validation for their use in upcoming clinical trials.

Statement of Ethics

The study was approved by the local NHS Research Ethics Committee and the Health Research Authority. All individuals gave informed written consent. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Disclosure Statement

H.Z. has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Biogen and Alzecure, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (all outside the submitted work). The other authors declare that they have no competing interests. No other authors have any conflicts of interest.

References

- 1 Woollacott IO, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *J Neurochem*. 2016 Aug;138 Suppl 1:6–31.
- 2 Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from post-mortem studies [Internet]. *J Neurochem*. 2016 Aug;138 Suppl 1:54–70. Available from: <http://doi.wiley.com/10.1111/jnc.13588>
- 3 Lashley T, Rohrer JD, Mead S, Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. *Neuropathol Appl Neurobiol*. 2015 Dec;41(7):858–81.
- 4 Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang H-Y, et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. *Cell*. 2016;165:921–35.
- 5 Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury [Internet]. *J Clin Invest*. 2012 Nov;122(11):3955–9. Available from: <http://www.jci.org/articles/view/63113>
- 6 Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease [Internet]. *J Neurol Neurosurg Psychiatry*. 2013 Sep;84(9):956–62. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23543794>
- 7 Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice [Internet]. *J Exp Med*. 2010 Jan;207(1):117–28. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2812536&tool=pmcentrez&rendertype=abstract>
- 8 Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein [Internet]. *Am J Pathol*. 2004 Nov;165(5):1643–52. [cited 2019 Apr 19] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15509534>
- 9 Bellucci A, Bugiani O, Ghetti B, Spillantini MG. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. *Neurodegener Dis*. 2011;8(4):221–9.
- 10 Lant SB, Robinson AC, Thompson JC, Rollinson S, Pickering-Brown S, Snowden JS, et al. Patterns of microglial cell activation in frontotemporal lobar degeneration. *Neuropathol Appl Neurobiol*. 2014 Oct;40(6):686–96.

Funding Sources

This work was funded by the Medical Research Council (MRC) UK. The authors acknowledge the support of the National Institute for Health Research (NIHR) Queen Square Dementia Biomedical Research Unit and the University College London Hospitals Biomedical Research Centre; the Leonard Wolfson Experimental Neurology Centre; the MRC Dementias Platform UK and the UK Dementia Research Institute. The Dementia Research Centre is an Alzheimer's Research UK coordinating centre and is supported by Alzheimer's Research UK, the Brain Research Trust and the Wolfson Foundation. I.O.C.W. was funded by an MRC Clinical Research Training Fellowship (MR/M018288/1). K.M.M. is supported by an Alzheimer's Society PhD Studentship. R.W.P. is funded by an NIHR Clinical Lectureship. A.K. is the recipient of a PhD Fellowship awarded by the Wolfson Foundation and a grant from the Weston Brain Institute. J.D.W. has received funding support from the Alzheimer's Society. J.M.S. acknowledges the support of the EPSRC (EP/J020990/1), MRC Dementias Platform UK (MR/L023784/1), ARUK (ARUK-Network 2012-6-ICE; ARUK-PG2017-1946; ARUK-PG2017-1946), Brain Research UK (UCC14191, Weston Brain Institute [UB170045] and European Union's Horizon 2020 research and innovation programme [Grant 666992]). H.Z. is a Wallenberg Academy Fellow. J.D.R. is an MRC Clinician Scientist (MR/M008525/1) and has received funding from the NIHR Rare Diseases Translational Research Collaboration (BRC149/NS/MH), the Bluefield Project and the Association for Frontotemporal Degeneration.

Author Contributions

I.O.C.W. and J.D.R. were involved in study design. All authors were involved in data collection. I.O.C.W., C.H., and M.S.F. were involved in data analysis. All authors were involved in drafting and critically revising the manuscript.

- 11 Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. *Sci Rep*. 2016;6:23204.
- 12 Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease [Internet]. *Sci Transl Med*. 2016 Jul;8(347):347ra93. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27412785> <http://stm.sciencemag.org/content/scitransmed/8/347/347ra93.full.pdf>
- 13 Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, Grinberg LT, et al. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts. *Neurol Neuroimmunol Neuroinflamm*. 2016 Oct 28;3(6):e301.
- 14 O'Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AK, et al. C9orf72 is required for proper macrophage and microglial function in mice. *Science*. 2016 Mar 18; 351(6279):1324-9.
- 15 Schludi MH, Becker L, Garrett L, Gendron TF, Zhou Q, Schreiber F, et al. Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. *Acta Neuropathol*. 2017 Aug; 134(2):241-54.
- 16 Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U, et al.; International FTD-Genomics Consortium (IFGC). A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain*. 2018 Oct; 141(10):2895-907.
- 17 Broce I, Karch CM, Wen N, Fan CC, Wang Y, Hong Tan C, et al. Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies. *PLoS Med*. 2018;15:1-20.
- 18 Ferrari R, Wang Y, Vandrovicova J, Guelfi S, Witeolar A, Karch CM, et al.; International FTD-Genomics Consortium (IFGC); International Parkinson's Disease Genomics Consortium (IPDGC); International Genomics of Alzheimer's Project (IGAP). Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. *J Neurol Neurosurg Psychiatry*. 2017 Feb;88(2):152-64.
- 19 Galimberti D, Bonsi R, Fenoglio C, Serpente M, Cioffi SMG, Fumagalli G, et al. Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. *Brain Behav Immun*. 2015; 49:182-7.
- 20 Katisko K, Solje E, Koivisto AM, Krüger J, Kinnunen T, Hartikainen P, et al. Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers. *J Neuroimmunol*. 2018;321:29-35.
- 21 Woollacott IOC, Bocchetta M, Sudre CH, Ridha BH, Strand C, Courtney R, et al. Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. *Neurocase*. 2018;24:166-74.
- 22 Clayton EL, Mancuso R, Nielsen TT, Mizielinska S, Holmes H, Powell N, et al.; FReJA. Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation [Internet]. *Hum Mol Genet*. 2017 Mar; 26(5):873-87. [cited 2017 Feb 11] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28093491>
- 23 Kim G, Ahmadian SS, Peterson M, Parton Z, Memon R, Weintraub S, et al. Asymmetric pathology in primary progressive aphasia with progranulin mutations and TDP inclusions. *Neurology*. 2016 Feb;86(7):627-36.
- 24 Kim G, Vahedi S, Gefen T, Weintraub S, Bigio EH, Mesulam MM, et al. Asymmetric TDP pathology in primary progressive aphasia with right hemisphere language dominance. *Neurology*. 2018 Jan;90(5):e396-403.
- 25 Kim G, Bolbolan K, Gefen T, Weintraub S, Bigio EH, Rogalski E, et al. Atrophy and microglial distribution in primary progressive aphasia with transactive response DNA-binding protein-43 kDa. *Ann Neurol*. 2018 Jun; 83(6):1096-104.
- 26 Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, et al. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. *J Alzheimers Dis*. 2017;55(3):1083-99.
- 27 Ohm DT, Kim G, Gefen T, Rademaker A, Weintraub S, Bigio EH, et al. Prominent microglial activation in cortical white matter is selectively associated with cortical atrophy in primary progressive aphasia. *Neuropathol Appl Neurobiol*. 2019 Apr;45(3):216-229.
- 28 Schofield E, Kersaitis C, Shepherd CE, Kril JJ, Halliday GM. Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. *Brain*. 2003 Apr;126(Pt 4):827-40.
- 29 Taipa R, Brochado P, Robinson A, Reis I, Costa P, Mann DM, et al. Patterns of Microglial Cell Activation in Alzheimer Disease and Frontotemporal Lobar Degeneration. *Neurodegener Dis*. 2017;17(4-5):145-54.
- 30 Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease [Internet]. *Acta Neuropathol*. 2009 Oct;118(4):475-85. [cited 2018 Jan 26] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19513731>
- 31 Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. *J Neurochem*. 2002 Dec; 83(6):1309-20.
- 32 Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. *Sci Transl Med*. 2014;6:243ra86-243ra86.
- 33 Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H. Diagnostic function of the neuro-inflammation biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. *Expert Rev Proteomics*. 2017;14: 285-99.
- 34 Mishra PS, Vijayalakshmi K, Nalini A, Sathyaprabha TN, Kramer BW, Alladi PA, et al. Etiogenic factors present in the cerebrospinal fluid from amyotrophic lateral sclerosis patients induce predominantly pro-inflammatory responses in microglia. *J Neuroinflammation*. 2017;14(1):1-18.
- 35 Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. *J Clin Invest*. 1994 Mar;93(3):1288-92.
- 36 Elmonem MA, van den Heuvel LP, Levchenko EN. Immunomodulatory Effects of Chitotriosidase Enzyme. *Enzyme Res*. 2016; 2016:2682680.
- 37 Woollacott IO, Nicholas JM, Heslegrave A, Heller C, Foiani MS, Dick KM, et al. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. *Alzheimers Res Ther*. 2018;10(1):1-14.
- 38 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia [Internet]. *Brain*. 2011 Sep;134(Pt 9):2456-77. [cited 2019 Apr 19] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21810890>
- 39 Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants [Internet]. *Neurology*. 2011 Mar; 76(11):1006-14. [cited 2019 Apr 19] Available from: <http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e31821103e6>
- 40 Paterson RW, Heywood WE, Heslegrave AJ, Magdalino NK, Andreasson U, Sirka E, et al. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology [Internet]. *Transl Psychiatry*. 2016 Nov; 6(11):e952.
- 41 Boot RG, Renkema GH, Verhoek M, Strijland A, Blik J, de Meulemeester TM, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. *J Biol Chem*. 1998 Oct; 273(40):25680-5.
- 42 Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, et al. Relationship between β -Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. *J Alzheimers Dis*. 2014;42(1):157-67.

- 43 Alcolea D, Vilaplana E, Suárez-Calvet M, Illán-Gala I, Blesa R, Clarimón J, et al. CSF sAPP β , YKL-40, and neurofilament light in frontotemporal lobar degeneration. *Neurology*. 2017 Jul;89(2):178–88.
- 44 Alcolea D, Irwin DJ, Illán-Gala I, Muñoz L, Clarimón J, McMillan CT, et al. Elevated YKL-40 and low sAPP β :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. *J Neurol Neurosurg Psychiatry*. 2019 Feb;90(2):180–6.
- 45 Del Campo M, Galimberti D, Elias N, Boonkamp L, Pijnenburg YA, van Swieten JC, et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. *Ann Clin Transl Neurol*. 2018 Sep;5(10):1163–75.
- 46 Illán-Gala I, Alcolea D, Montal V, Dols-Icardo O, Muñoz L, de Luna N, et al. CSF sAPP β , YKL-40, and NfL along the ALS-FTD spectrum. *Neurology*. 2018 Oct;91(17):e1619–28.
- 47 Janelidze S, Hertzze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. *Ann Clin Transl Neurol*. 2015 Nov;3(1):12–20.
- 48 Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, et al.; German Consortium for Frontotemporal Lobar Degeneration. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. *J Neurol Neurosurg Psychiatry*. 2019 Jan;90(1):4–10.
- 49 Teunissen CE, Elias N, Koel-Simmeling MJA, Durieux-Lu S, Malekzadeh A, Pham TV, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. *Alzheimers Dement (Amst)*. 2016 Jan 19;2:86–94.
- 50 Vijverberg EGB, Dols A, Krudop WA, Del Campo Milan M, Kerstens CJ, Gossink F, et al. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. *Alzheimers Dement (Amst)*. 2017 Mar 2;7:99–106.
- 51 Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, et al.; FTLDC study group. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. *J Neurol Neurosurg Psychiatry*. 2018 Mar;89(3):239–47.
- 52 Andrés-Benito P, Domínguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. *Aging (Albany NY)*. 2018 Sep;10(9):2367–82.
- 53 Sanfilippo C, Longo A, Lazzara F, Cambria D, Distefano G, Palumbo M, et al. CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients. *Mol Cell Neurosci*. 2017 Dec;85:162–9.
- 54 Thompson AG, Gray E, Thézénas ML, Charles PD, Evetts S, Hu MT, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. *Ann Neurol*. 2018 Feb;83(2):258–68.
- 55 Varghese AM, Sharma A, Mishra P, Vijayalakshmi K, Harsha HC, Sathyaprabha TN, et al. Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. *Clin Proteomics*. 2013 Dec;10(1):19.
- 56 Chen X, Chen Y, Wei Q, Ou R, Cao B, Zhao B, et al. Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis [Internet]. *BMC Neurol*. 2016 Sep;16(1):173.
- 57 Pagliardini V, Pagliardini S, Corrado L, Lucetti A, Panigati L, Bersano E, et al. Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study [Internet]. *J Neurol Sci*. 2015 Jan;348(1-2):245–50.
- 58 Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease [Internet]. *Biol Psychiatry*. 2010 Nov;68(10):903–12. [cited 2019 Apr 19] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21035623>
- 59 Rosén C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L, et al. Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. *Dement Geriatr Cogn Disord Extra*. 2014 Jul;4(2):297–304.
- 60 Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort [Internet]. *Alzheimers Res Ther*. 2015 Sep;7(1):59.
- 61 Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies. *PLoS One*. 2015 Aug;10(8):e0135458.
- 62 Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias [Internet]. *Mol Neurodegener*. 2017 Nov;12(1):83. Available from: <https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-017-0226-4>
- 63 Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease [Internet]. *Alzheimers Res Ther*. 2015 Dec;7(1):74.
- 64 Gispert JD, Monté GC, Falcon C, Tucholka A, Rojas S, Sánchez-Valle R, et al. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. *Neurobiol Aging*. 2016;38:47–55.
- 65 Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. *J Alzheimers Dis*. 2014;42(3):901–8.
- 66 Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al.; Alzheimer Precision Medicine Initiative (APMI). Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β 1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. *Alzheimers Dement*. 2018 Apr;14(4):492–501.
- 67 Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, et al. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. *J Alzheimers Dis*. 2016;50:873–86.
- 68 Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. *Alzheimers Dement*. 2018;14:869–79.
- 69 Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, et al. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40 [Internet]. *BMC Neurol*. 2016 Nov;16(1):217.
- 70 Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease [Internet]. *Mol Neurodegener*. 2016 Jan;11(1):3. Available from: <http://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-016-0071-x>
- 71 Gispert JD, Suárez-Calvet M, Monté GC, Tucholka A, Falcon C, Rojas S, et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. *Alzheimers Dement*. 2016 Dec;12(12):1259–72.
- 72 Suárez-Calvet M, Kleinberger G, Araque-Caballero MÁ, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers [Internet]. *EMBO Mol Med*. 2016 May;8(5):466–76. [cited 2017 Feb 11] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26941262>
- 73 Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al.; Dominantly Inherited Alzheimer Network. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. *Sci Transl Med*. 2016 Dec;8(369):369ra178.

- 74 Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Månsson JE, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility [Internet]. *Neuromolecular Med*. 2011 Jun;13(2):151–9. Available from: <http://link.springer.com/10.1007/s12017-011-8147-9>
- 75 Watabe-Rudolph M, Song Z, Lausser L, Schnack C, Begus-Nahrman Y, Scheithauer MO, et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. *Neurology*. 2012 Feb;78(8):569–77.
- 76 Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, et al. Glial fibrillary acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. *J Neurochem*. 2016 Jan;136(2):258–61.
- 77 Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, et al. Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. *J Alzheimers Dis*. 2009;17(3):541–51.
- 78 Fukuyama R, Izumoto T, Fushiki S. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia. *Eur Neurol*. 2001;46(1):35–8.
- 79 Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100 β in the cerebrospinal fluid of patients with frontotemporal dementia. *Neurosci Lett*. 1997 Oct;235(1-2):5–8.
- 80 Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. *Neurochem Int*. 2001 Nov-Dec;39(5-6):409–13.
- 81 Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. *Neurosci Lett*. 2003 Jan;336(3):167–70.
- 82 Navarro V, Sanchez-Mejias E, Jimenez S, Muñoz-Castro C, Sanchez-Varo R, Davila JC, et al. Microglia in Alzheimer's disease: Activated, dysfunctional or degenerative. *Front Aging Neurosci*. 2018 May;10:140.
- 83 Alquézar C, de la Encarnación A, Moreno F, López de Munain A, Martín-Requero Á. Progranulin deficiency induces overactivation of WNT5A expression via TNF- α /NF- κ B pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers. *J Psychiatry Neurosci*. 2016 Jun;41(4):225–39.
- 84 Bossù P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, et al. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. *J Neuroinflammation*. 2011;8:65.
- 85 Gibbons L, Rollinson S, Thompson JC, Robinson A, Davidson YS, Richardson A, et al. Plasma levels of progranulin and interleukin-6 in frontotemporal lobar degeneration. *Neurobiol Aging*. 2015;36:1603.e1–e4.
- 86 Kleinberger G, Capell A, Haass C, Van Broeckhoven C. Mechanisms of granulin deficiency: lessons from cellular and animal models. *Mol Neurobiol*. 2013 Feb;47(1):337–60.
- 87 Götzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. *Acta Neuropathol*. 2014;127(6):845–60.
- 88 Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis [Internet]. *Sci Transl Med*. 2017 Apr;9(385):eaah5642. Available from: <http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aah5642>
- 89 Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease [Internet]. *Ann Neurol*. 1997 Oct;42(4):613–21.
- 90 Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiffmann R, Futerman AH. Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease. *PLoS One*. 2015 Mar;10(3):e0120194.
- 91 Jian J, Chen Y, Liberti R, Fu W, Hu W, Saunders-Pullman R, et al. Chitinase-3-like protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease [Internet]. *EBioMedicine*. 2018 Feb;28:251–60.
- 92 Drugan C, Drugan TC, Grigorescu-Sido P, Naşcu I. Modelling long-term evolution of chitotriosidase in non-neuronopathic Gaucher disease. *Scand J Clin Lab Invest*. 2017 Jul;77(4):275–82.
- 93 Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, et al. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. *J Alzheimers Dis*. 2013;33(1):45–53.
- 94 Zhang H, Ng KP, Therriault J, Kang MS, Pascoal TA, Rosa-Neto P, et al. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. *Transl Neurodegener*. 2018;7(1):1–12.
- 95 Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martín-Paniello C, Clarimon J, Belbin O, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. *J Neuroinflammation*. 2017;14(1):1–10.